Automate Your Wheel Strategy on ABBV
With Tiblio's Option Bot, you can configure your own wheel strategy including ABBV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ABBV
- Rev/Share 33.6591
- Book/Share -1.4667
- PB -146.6897
- Debt/Equity -26.0193
- CurrentRatio 0.7245
- ROIC 0.187
- MktCap 386508078405.0
- FreeCF/Share 11.6078
- PFCF 18.7908
- PE 161.8856
- Debt/Assets 0.5134
- DivYield 0.03
- ROE 4.9875
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ABBV | DZ Bank | Buy | Hold | -- | $237 | Nov. 4, 2025 |
| Downgrade | ABBV | Erste Group | Buy | Hold | -- | -- | Oct. 14, 2025 |
| Downgrade | ABBV | HSBC Securities | Buy | Hold | -- | -- | Oct. 1, 2025 |
| Upgrade | ABBV | Berenberg | Hold | Buy | -- | $270 | Sept. 17, 2025 |
| Resumed | ABBV | Piper Sandler | -- | Overweight | -- | $231 | Aug. 12, 2025 |
| Upgrade | ABBV | Daiwa Securities | Neutral | Outperform | -- | $214 | Aug. 7, 2025 |
| Downgrade | ABBV | Citigroup | Buy | Neutral | -- | $205 | May 14, 2025 |
| Initiation | ABBV | Cantor Fitzgerald | -- | Overweight | -- | $210 | April 22, 2025 |
| Resumed | ABBV | BofA Securities | -- | Neutral | -- | $191 | Dec. 10, 2024 |
| Downgrade | ABBV | Daiwa Securities | Outperform | Neutral | -- | $180 | Dec. 5, 2024 |
News
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Read More
AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript
Published: October 31, 2025 by: Seeking Alpha
Sentiment: Neutral
AbbVie Inc. ( ABBV ) Q3 2025 Earnings Call October 31, 2025 9:00 AM EDT Company Participants Elizabeth Shea - Senior Vice President of Investor Relations Robert Michael - CEO & Chairman of the Board Jeffrey Stewart - Executive VP & Chief Commercial Officer Roopal Thakkar - Executive VP of Research and Development & Chief Scientific Officer Scott Reents - Executive VP & CFO Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Vamil Divan - Guggenheim Securities, LLC, Research Division Matthew Phipps - William Blair & Company L.L.C., Research …
Read More
AbbVie Q3 Earnings & Sales Beat, 2025 EPS Outlook Raised
Published: October 31, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV tops Q3 earnings and revenue estimates, driven by Rinvoq and Skyrizi gains, and lifts its 2025 EPS outlook.
Read More
Demographic Megatrend: Stocks Poised to Benefit From Global Aging
Published: October 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Global aging is reshaping healthcare demand. Discover how AbbVie, Amgen, Boston Scientific and Edwards are positioned to gain from this powerful megatrend.
Read More
AbbVie (ABBV) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Published: October 31, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
AbbVie: Why Q3 Confirms Its Immunology Dominance
Published: October 31, 2025 by: Seeking Alpha
Sentiment: Positive
AbbVie Inc., 2 hours ago, published monstrous results for Q3, once again strengthening my confidence that it is a "powerhouse" in the autoimmune disease drugs market. Net revenues from AbbVie's immunology portfolio totaled $7.89 billion this quarter, compared to $7.05 billion in Q3 2024. Sales of Elahere, an ADC used to treat ovarian cancer, reached $170 million in Q3 2025, up 22.3% year-on-year and 6.9% quarter-on-quarter.
Read More
AbbVie (ABBV) Q3 Earnings and Revenues Surpass Estimates
Published: October 31, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie (ABBV) came out with quarterly earnings of $1.86 per share, beating the Zacks Consensus Estimate of $1.77 per share. This compares to earnings of $3 per share a year ago.
Read More
5 Dividend ETFs That Could Pay You for Life
Published: October 31, 2025 by: 24/7 Wall Street
Sentiment: Positive
Whether you're just beginning to invest or sailing into retirement, you can benefit from a lifetime stream of passive income.
Read More
AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo
Published: October 29, 2025 by: PRNewsWire
Sentiment: Neutral
In two replicate Phase 3 studies, upadacitinib (RINVOQ ® ) achieved the co-primary endpoints of 50% reduction in Total Vitiligo Area Scoring Index (T-VASI 50) from baseline and 75% reduction in Facial Vitiligo Area Scoring Index (F-VASI 75) from baseline at week 481 Both studies met key ranked secondary endpoints1 NORTH CHICAGO, Ill. , Oct. 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from two replicate Phase 3 studies evaluating the safety and efficacy of upadacitinib (RINVOQ®;15 mg, once daily in adult and adolescent patients living with non-segmental vitiligo (NSV).1 NSV, the most common form of …
Read More
AbbVie: Deep Discount Before Earnings
Published: October 28, 2025 by: Seeking Alpha
Sentiment: Positive
AbbVie Inc. is reiterated as a Strong Buy ahead of Q3 earnings, with revenue growth expected to outpace the sector median. ABBV consistently delivers double beats, maintains robust FCF margins, and is investing aggressively in R&D for future growth. The DDM model suggests ABBV is significantly undervalued, with a fair value estimate indicating 27% upside potential over the next year.
Read More
Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings
Published: October 28, 2025 by: CNBC
Sentiment: Positive
Eli Lilly, Merck, Gilead, Bristol Myers Squibb and AbbVie, among other pharmaceutical companies, are slated to report third-quarter earnings this week.
Read More
Should You Buy AbbVie Stock Ahead of Q3 Earnings Report?
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Negative
ABBV's Q3 results are likely to hinge on Skyrizi and Rinvoq growth, as Humira erosion and hefty IPR&D charges are expected to pressure near-term earnings.
Read More
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Neutral
As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.
Read More
Analysts Estimate AbbVie (ABBV) to Report a Decline in Earnings: What to Look Out for
Published: October 24, 2025 by: Zacks Investment Research
Sentiment: Negative
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Wall Street Analysts Think AbbVie (ABBV) Is a Good Investment: Is It?
Published: October 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Read More
AbbVie Up More Than 30% in 6 Months: How to Play the Stock
Published: October 22, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie's 30% surge in six months is powered by booming sales of Skyrizi and Rinvoq and renewed strength across oncology and neuroscience.
Read More
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
Published: October 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Read More
The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients
Published: October 21, 2025 by: PRNewsWire
Sentiment: Neutral
Each winner will be awarded a $20,000 grant to fuel their businesses. Since the program's inception, BOTOX® Cosmetic has awarded more than $1 million in grants to The Confidence Project entrepreneurs.
Read More
Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Neutral
ABBV's oncology lineup, spanning blood and solid tumor drugs, faces modest Q3 growth as new launches offset Imbruvica's decline.
Read More
AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin
Published: October 17, 2025 by: PRNewsWire
Sentiment: Neutral
Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD). NORTH CHICAGO, Ill.
Read More
Can Rinvoq and Skyrizi Sales Drive Another Strong Quarter for AbbVie?
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV leans on booming Skyrizi and Rinvoq-driven sales to sustain growth and counter Humira's decline as Q3 results approach.
Read More
Final Trades: Abbvie, Amazon, Datadog and Sixth Street Specialty Lending
Published: October 13, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease
Published: October 13, 2025 by: PRNewsWire
Sentiment: Neutral
- Updated indication allows the use of RINVOQ® (upadacitinib) prior to the use of tumor necrosis factor (TNF) blocking agents in patients for whom use of these treatments is clinically inadvisable and who have received at least one approved systemic therapy NORTH CHICAGO, Ill. , Oct. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) approval of a supplemental new drug application (sNDA) that updates the indication statement for RINVOQ® (upadacitinib) for the treatment of adults with moderately to severely active ulcerative colitis (UC) and moderately to severely active Crohn's disease (CD).
Read More
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
AbbVie vs. Eli Lilly: Which Large Drugmaker Has the Edge in 2025?
Published: October 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Lilly's explosive GLP-1 growth and AbbVie's post-Humira rebound set up a fierce 2025 showdown between two pharma powerhouses.
Read More
My Top 5 Biotech Stocks Big Pharma Could Buy Next
Published: October 06, 2025 by: Seeking Alpha
Sentiment: Positive
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.
Read More
AbbVie Stock on the Move: What Sparked the 6% Jump in the Past Week?
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV shares rose 6% last week as optimism swept the pharma sector after Pfizer's landmark drug-pricing deal with the Trump administration.
Read More
AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor
Published: October 06, 2025 by: PRNewsWire
Sentiment: Neutral
OnabotulinumtoxinA (BOTOX®) met the primary endpoint in the Phase 2 trial, demonstrating a statistically significant improvement from baseline in the Tremor Disability Scale-Revised (TREDS-R) total unilateral score compared to placebo.1 The trial also met all six secondary endpoints.2 Results from safety analyses were generally consistent with the well-established safety profile of onabotulinumtoxinA.1 NORTH CHICAGO, Ill. , Oct. 6, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 2 ELATE trial evaluating the safety and efficacy of onabotulinumtoxinA (BOTOX®) compared to placebo for the treatment of upper limb essential tremor.
Read More
AbbVie: Wins Accumulating While We Wait For Next BD Steps
Published: October 03, 2025 by: Seeking Alpha
Sentiment: Positive
AbbVie is outperforming expectations with strong commercial results, pipeline progress, and the legal win that secured Rinvoq's long-term market exclusivity. ABBV has raised the full-year revenue guidance by $1.5 billion since the start of the year, and I am raising my estimate range again to reflect the better-than-expected performance. The pipeline is delivering late-stage wins, notably with Rinvoq, Epkinly, and Qulipta.
Read More
AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S.
Published: September 30, 2025 by: PRNewsWire
Sentiment: Neutral
Expansion increases biologics manufacturing for immunology and oncology medicines Milestone marks progress on AbbVie's long-term commitment to U.S. manufacturing Furthers longstanding commitment to AbbVie's Massachusetts sites and workforce NORTH CHICAGO, Ill. , Sept. 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the start of construction of a $70 million expansion at its AbbVie Bioresearch Center (ABC) in Worcester, Mass.
Read More
About AbbVie Inc. (ABBV)
- IPO Date 2013-01-02
- Website https://www.abbvie.com
- Industry Drug Manufacturers - General
- CEO Robert A. Michael CPA
- Employees 55000